Literature DB >> 26323538

PCSK9 inhibitors are go.

Asher Mullard.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26323538     DOI: 10.1038/nrd4730

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  1 in total

Review 1.  Validating therapeutic targets through human genetics.

Authors:  Robert M Plenge; Edward M Scolnick; David Altshuler
Journal:  Nat Rev Drug Discov       Date:  2013-07-19       Impact factor: 84.694

  1 in total
  3 in total

1.  Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.

Authors:  Gabrielle N Winston-McPherson; Haibo Xie; Ka Yang; Xiaoxun Li; Dongxu Shu; Weiping Tang
Journal:  Bioorg Med Chem Lett       Date:  2019-06-12       Impact factor: 2.823

2.  Immune cell screening of a nanoparticle library improves atherosclerosis therapy.

Authors:  Jun Tang; Samantha Baxter; Arjun Menon; Amr Alaarg; Brenda L Sanchez-Gaytan; Francois Fay; Yiming Zhao; Mireille Ouimet; Mounia S Braza; Valerie A Longo; Dalya Abdel-Atti; Raphael Duivenvoorden; Claudia Calcagno; Gert Storm; Sotirios Tsimikas; Kathryn J Moore; Filip K Swirski; Matthias Nahrendorf; Edward A Fisher; Carlos Pérez-Medina; Zahi A Fayad; Thomas Reiner; Willem J M Mulder
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

3.  Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research.

Authors:  Ciska Verbaanderd; Ilse Rooman; Isabelle Huys
Journal:  Trials       Date:  2021-05-04       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.